| 1.65 0.07 (4.43%) | 01-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.49 | 1-year : | 2.9 |
| Resists | First : | 2.13 | Second : | 2.48 |
| Pivot price | 1.9  |
|||
| Supports | First : | 1.58 | Second : | 1.31 |
| MAs | MA(5) : | 1.63 |
MA(20) : | 1.96 |
| MA(100) : | 2.24 |
MA(250) : | 2.04 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 4.6 |
D(3) : | 4.2 |
| RSI | RSI(14): 34 |
|||
| 52-week | High : | 3.09 | Low : | 1.07 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PRQR ] has closed above bottom band by 19.5%. Bollinger Bands are 40.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.58 - 1.59 | 1.59 - 1.6 |
| Close: | 1.63 - 1.65 | 1.65 - 1.67 |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Fri, 16 Jan 2026
ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Tue, 13 Jan 2026
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - simplywall.st
Tue, 13 Jan 2026
Why Investors Shouldn't Be Surprised By ProQR Therapeutics N.V.'s (NASDAQ:PRQR) 28% Share Price Plunge - Sahm
Thu, 08 Jan 2026
ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK - GlobeNewswire
Thu, 08 Jan 2026
ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below 50 Day Moving Average - Here's What Happened - MarketBeat
Thu, 08 Jan 2026
ProQR reports positive initial AX-0810 safety data in phase 1 trial - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 65 (M) |
| Held by Insiders | 18 (%) |
| Held by Institutions | 50.1 (%) |
| Shares Short | 1,270 (K) |
| Shares Short P.Month | 778 (K) |
| EPS | -0.48 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.63 |
| Profit Margin | -264.9 % |
| Operating Margin | -387.2 % |
| Return on Assets (ttm) | -24.1 % |
| Return on Equity (ttm) | -103.8 % |
| Qtrly Rev. Growth | -26.8 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.42 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -49 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -3.44 |
| PEG Ratio | 0 |
| Price to Book value | 2.57 |
| Price to Sales | 10.81 |
| Price to Cash Flow | -3.57 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|